Greg Harrison
Stock Analyst at Scotiabank
(2.95)
# 1,475
Out of 4,670 analysts
57
Total ratings
40.43%
Success rate
1.81%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Greg Harrison
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BBIO BridgeBio Pharma | Maintains: Sector Outperform | $44 → $45 | $23.42 | +92.14% | 2 | Nov 15, 2024 | |
| APLS Apellis Pharmaceuticals | Maintains: Sector Perform | $35 → $30 | $30.77 | -2.50% | 2 | Nov 6, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Sector Perform | $480 → $486 | $450.97 | +7.77% | 2 | Nov 5, 2024 | |
| IRON Disc Medicine | Maintains: Sector Outperform | $62 → $70 | $64.96 | +7.76% | 2 | Nov 5, 2024 | |
| TVTX Travere Therapeutics | Maintains: Sector Outperform | $23 → $27 | $18.25 | +47.95% | 7 | Nov 1, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Sector Outperform | $305 → $310 | $244.89 | +26.59% | 2 | Nov 1, 2024 | |
| AGIO Agios Pharmaceuticals | Maintains: Sector Outperform | $51 → $53 | $55.68 | -4.81% | 3 | Nov 1, 2024 | |
| VERA Vera Therapeutics | Initiates: Sector Outperform | $60 | $48.31 | +24.20% | 1 | Oct 16, 2024 | |
| KROS Keros Therapeutics | Initiates: Sector Outperform | $77 | $55.92 | +37.70% | 3 | Oct 16, 2024 | |
| EYPT EyePoint Pharmaceuticals | Initiates: Sector Outperform | $18 | $8.95 | +101.12% | 1 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Perform | $24 | $25.05 | -4.19% | 3 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $30 | $10.65 | +181.69% | 4 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $6 | $4.07 | +47.42% | 1 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $50 | $14.11 | +254.36% | 3 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $22 | $8.83 | +149.15% | 1 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $13 → $15 | $2.44 | +514.75% | 3 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $303 → $280 | $372.89 | -24.91% | 1 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $89 → $91 | $14.30 | +536.36% | 2 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $9 → $12 | $11.43 | +4.99% | 3 | May 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $5 → $1.5 | $1.88 | -20.21% | 1 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $39 | $12.49 | +212.25% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $3 | $10.91 | -72.50% | 1 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $2.17 | +3,124.91% | 1 | Sep 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $8 | $20.21 | -60.42% | 1 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $67 → $54 | $28.54 | +89.21% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $18 → $6 | $1.05 | +471.43% | 5 | Mar 14, 2022 |
BridgeBio Pharma
Nov 15, 2024
Maintains: Sector Outperform
Price Target: $44 → $45
Current: $23.42
Upside: +92.14%
Apellis Pharmaceuticals
Nov 6, 2024
Maintains: Sector Perform
Price Target: $35 → $30
Current: $30.77
Upside: -2.50%
Vertex Pharmaceuticals
Nov 5, 2024
Maintains: Sector Perform
Price Target: $480 → $486
Current: $450.97
Upside: +7.77%
Disc Medicine
Nov 5, 2024
Maintains: Sector Outperform
Price Target: $62 → $70
Current: $64.96
Upside: +7.76%
Travere Therapeutics
Nov 1, 2024
Maintains: Sector Outperform
Price Target: $23 → $27
Current: $18.25
Upside: +47.95%
Alnylam Pharmaceuticals
Nov 1, 2024
Maintains: Sector Outperform
Price Target: $305 → $310
Current: $244.89
Upside: +26.59%
Agios Pharmaceuticals
Nov 1, 2024
Maintains: Sector Outperform
Price Target: $51 → $53
Current: $55.68
Upside: -4.81%
Vera Therapeutics
Oct 16, 2024
Initiates: Sector Outperform
Price Target: $60
Current: $48.31
Upside: +24.20%
Keros Therapeutics
Oct 16, 2024
Initiates: Sector Outperform
Price Target: $77
Current: $55.92
Upside: +37.70%
EyePoint Pharmaceuticals
Oct 16, 2024
Initiates: Sector Outperform
Price Target: $18
Current: $8.95
Upside: +101.12%
Oct 16, 2024
Initiates: Sector Perform
Price Target: $24
Current: $25.05
Upside: -4.19%
Oct 16, 2024
Initiates: Sector Outperform
Price Target: $30
Current: $10.65
Upside: +181.69%
Oct 16, 2024
Initiates: Sector Outperform
Price Target: $6
Current: $4.07
Upside: +47.42%
Oct 16, 2024
Initiates: Sector Outperform
Price Target: $50
Current: $14.11
Upside: +254.36%
Oct 16, 2024
Initiates: Sector Outperform
Price Target: $22
Current: $8.83
Upside: +149.15%
Aug 8, 2024
Upgrades: Buy
Price Target: $13 → $15
Current: $2.44
Upside: +514.75%
Aug 1, 2024
Maintains: Underperform
Price Target: $303 → $280
Current: $372.89
Upside: -24.91%
Jun 13, 2023
Maintains: Buy
Price Target: $89 → $91
Current: $14.30
Upside: +536.36%
May 1, 2023
Upgrades: Neutral
Price Target: $9 → $12
Current: $11.43
Upside: +4.99%
Apr 28, 2023
Downgrades: Underperform
Price Target: $5 → $1.5
Current: $1.88
Upside: -20.21%
Mar 7, 2023
Initiates: Buy
Price Target: $39
Current: $12.49
Upside: +212.25%
Nov 8, 2022
Downgrades: Underperform
Price Target: $3
Current: $10.91
Upside: -72.50%
Sep 29, 2022
Initiates: Buy
Price Target: $70
Current: $2.17
Upside: +3,124.91%
Jun 8, 2022
Upgrades: Neutral
Price Target: $8
Current: $20.21
Upside: -60.42%
Mar 16, 2022
Maintains: Buy
Price Target: $67 → $54
Current: $28.54
Upside: +89.21%
Mar 14, 2022
Downgrades: Underperform
Price Target: $18 → $6
Current: $1.05
Upside: +471.43%